更新于：2024-11-04
Danaparoid Sodium
达那类肝素钠
更新于：2024-11-04
概要
基本信息
在研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床申请批准 |
特殊审评- |
登录后查看时间轴
关联
8
项与 达那类肝素钠 相关的临床试验An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study) - HITSOVA
An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study) - HITSOVA
Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT
100 项与 达那类肝素钠 相关的临床结果
登录后查看更多信息
100 项与 达那类肝素钠 相关的转化医学
登录后查看更多信息
100 项与 达那类肝素钠 相关的专利（医药）
登录后查看更多信息
1,152
项与 达那类肝素钠 相关的文献（医药）2024-10-01STROKE
Sex-Stratified Genome-Wide Association Study in the Spanish Population Identifies a Novel Locus for Lacunar Stroke
Article
作者: Heitsch, Laura ; Vives-Bauza, Cristòfol ; Lee, Jin-Moo ; Arenillas, Juan Francisco ; Muiño, Elena ; Camps-Renom, Pol ; Dhar, Rajat ; Sumoy, Lauro ; Muñoz-Narbona, Lucia ; Montaner, Joan ; Gallego-Fabrega, Cristina ; Krupinski, Jerzy ; Ribó, Marc ; Obach, Victor ; Cullell, Natalia ; Cruchaga, Carlos ; Serrano-Heras, Gemma ; Delgado, Pilar ; Sobrino, Tomás ; Roquer, Jaume ; Llucià-Carol, Laia ; Ibañez, Laura ; Martí-Fàbregas, Joan ; Ezcurra, Garbiñe ; Prats-Sánchez, Luis ; Diaz-Navarro, Rosa ; de Cid, Rafael ; Férnandez-Cadenas, Israel ; Molina, Carlos A. ; Millán, Mònica ; Lopez-Cancio, Elena ; Guasch, Marina ; Álvarez-Sabín, José ; Blay, Natalia ; Castillo, José ; Freijo, Marimar ; Campos, Francisco ; Jiménez-Conde, Jordi ; Martín-Campos, Jesús M. ; Lledós, Miquel ; Segura, Tomás ; Cárcel-Márquez, Jara
BACKGROUND::
Ischemic stroke (IS) represents a significant health burden globally, necessitating a better understanding of its genetic underpinnings to improve prevention and treatment strategies. Despite advances in IS genetics, studies focusing on the Spanish population and sex-stratified analyses are lacking.
METHODS::
A case-control genome-wide association study was conducted with 9081 individuals (3493 IS cases and 5588 healthy controls). IS subtypes using Trial of ORG 10172 in Acute Stroke Treatment criteria were explored in a sex-stratified approach. Replication efforts involved the MEGASTROKE, GIGASTROKE, and the UK Biobank international cohorts. Post-genome-wide association study analysis included: in silico proteomic analysis, gene-based analysis, quantitative trait loci annotation, transcriptome-wide association analysis, and bioinformatic analysis using chromatin accessibility data.
RESULTS::
Identified as associated with IS and its subtypes were 4 significant and independent loci. Replication confirmed 5p15.2 as a new locus associated with small-vessel occlusion stroke, with rs59970332-T as the lead variant (beta [SE], 0.13 [0.02];
P
=4.34×10
−8
). Functional analyses revealed
CTNND2
given proximity and its implication in pathways involved in vascular integrity and angiogenesis. Integration of Hi-C data identified additional potentially modulated genes, and in silico proteomic analysis suggested a distinctive blood proteome profile associated with the lead variant. Gene-set enrichment analyses highlighted pathways consistent with small-vessel disease pathogenesis. Gene-based associations with known stroke-related genes such as
F2
and
FGG
were also observed, reinforcing the relevance of our findings.
CONCLUSIONS::
We found
CTNND2
as a potential key molecule in small-vessel occlusion stroke risk, and predominantly in males. This study sheds light on the genetic architecture of IS in the Spanish population, providing novel insights into sex-specific associations and potential molecular mechanisms. Further research, including replication in larger cohorts, is essential for a comprehensive understanding of these findings and for their translation to clinical practice.
2024-09-02Cureus Journal of Medical Science
A Comprehensive Study of Risk Factors, Etiology, and Infarction Patterns in Cerebrovascular Accidents at a Tertiary Care Hospital in India
Article
作者: Yekkaluru, Sree Vidya ; Pancholi, Tushar ; Sangwan, Advit ; Mundada, Mayank ; Yammanuru, Bhavya ; Reddy, Raju Hansini ; Diggikar, Pradnya ; Oommen, Arun
Background Stroke is a debilitating cerebrovascular condition characterized by sudden neurological deficits. The incidence of stroke is rising in India, posing significant public health concerns. This study aims to examine the risk factors and etiology of stroke using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification and analyze infarct areas in cerebrovascular accidents (CVA) at a tertiary care hospital. Methodology This cross-sectional, hospital-based observational study was conducted at Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to Be University), Pune, India, from January 2023 to January 2024. The study included 100 adult patients diagnosed with CVA based on clinical and radiological criteria. Patients aged 18 years and older were eligible, while those with a history of head trauma or those below 18 years were excluded. The investigation protocol included routine biochemical assessments and radiological investigations, such as computed tomography (CT), magnetic resonance imaging (MRI) with angiography or venography, and Doppler ultrasound of bilateral carotid arteries. Results The study population consisted of 100 patients, with 84 males (84%) and 16 females (16%). Age distribution showed 44% were over 60 years old, 23% aged 51-60 years, 15% aged 31-40 years, 14% aged 41-50 years, and 4% aged 21-30 years. Hypertension was the most prevalent risk factor, affecting 75% of patients, with a higher occurrence in males (62%), compared to females (13%). Smoking was observed in 51% of patients, and alcohol consumption was seen in 50%. Other significant risk factors included dyslipidemia (39%), diabetes mellitus (33%), chronic kidney disease (11%), ischemic heart disease (10%), atrial fibrillation (4%), valvular heart disease (4%), and pregnancy or postpartum conditions (2%). Ischemic stroke was predominant, occurring in 80% of patients, while hemorrhagic stroke occurred in 20%. High occurrences of ischemic strokes were noted in the frontal lobe (41%), parietal lobe (37%), occipital lobe (27%), and temporal lobe (26%), with the internal capsule region also showing significant numbers (27%). According to the TOAST classification, the most prevalent cause of stroke in this study was undetermined etiology with two or more causes, accounting for 32% of cases, followed by large artery atherosclerosis, which accounted for 30%. Cardioembolic stroke was identified in 11% of the patients, with 4% due to atrial fibrillation, 3% due to acute myocardial infarction, 3% due to rheumatic valvular heart disease, and 1% due to infective endocarditis. Conclusion This study highlights the significant prevalence of hypertension, smoking, alcohol consumption, and hyperhomocysteinemia as major risk factors for stroke. Ischemic strokes were predominant, with high occurrences in the cerebral lobes and gangliocapsular region. These findings emphasize the need for targeted prevention strategies, including managing hypertension and lifestyle modifications such as smoking cessation and reducing alcohol consumption, to mitigate the risk of stroke. Effective management of blood pressure, lipid levels, and blood glucose is crucial for stroke prevention. Recognizing gender-specific differences and addressing comorbidities through an integrated approach can enhance patient outcomes and reduce the burden of stroke.
2024-08-01Journal of Stroke & Cerebrovascular Diseases
Long-term outcomes among ischemic stroke TOAST subtypes: A 12-year Cohort study in China
Article
作者: Zhu, Cairong ; Hu, Meijing ; Jin, Yu ; Wu, Chenyao ; Yao, Qiang ; Lin, Yidie ; Yang, Jing
BACKGROUND:
Disparities in short-term ischemic stroke (IS) prognosis among Trial of Org 10172 in Acute Stroke Treatment (TOAST) subtypes were observed. Notably, little is known about the long-term prognosis of different subtypes in China. We aim to investigate the long-term outcome in IS patients and try to explore the potential interactive effects between IS subtypes and antithrombotic therapy.
METHODS:
This is a prospective cohort of stroke survivors. Patients diagnosed with first-ever IS at the Department of Neurology, West China Hospital, Sichuan University from January 2010 to December 2019 were recruited. They were followed until September 2022 to assess recurrence, mortality, and functional recovery. The multivariate Fine-Gray model assessed stroke recurrence, while Cox regression estimated hazard ratios. Modified Rankin Scale scores(mRS) were analyzed using the generalized linear mixed effects model.
RESULTS:
At baseline, 589 of 950 participants (62.00 %) were male. The longest follow-up was 150 months, the shortest was 1.5 months, and the median follow-up was 81.0 months. Cardio-embolism (CE) bore the highest mortality risk compared to large artery atherosclerosis (LAA) (HR=4.43,95 %CI 1.61-12.23). Among survivors on anticoagulant therapy, CE exhibited a reduced risk of mortality (HR = 0.18, 95 % CI 0.04-0.80). In function recovery, small artery occlusion (SAO) demonstrated more favorable prognostic outcomes (β=-2.08, P<0.01, OR=0.13,95 %CI 0.03-0.47). Among survivors taking antiplatelet drugs, SAO demonstrated a slower pace of functional recovery compared to LAA (β=1.39, P=0.05, OR=3.99,95 %CI 1.01-15.74).
CONCLUSIONS:
Long-term outcomes post-first IS vary among TOAST subtypes. Anticoagulant therapy offers long-term benefits among patients of the CE. However, prolonged administration of antiplatelet drugs among SAO patients may be limited in improving function recovery. Physicians should carefully consider treatment options for different IS subtypes to optimize patient outcomes and stroke care effectiveness.
100 项与 达那类肝素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 弥散性血管内凝血 | 日本 | 2001-04-20 | |
| 静脉血栓形成 | 美国 | 1996-12-24 | |
| 血栓栓塞 | 荷兰 | 1991-06-10 | |
| 血小板减少症 | 荷兰 | - | 1991-01-01 |
| 静脉血栓栓塞 | 荷兰 | - | 1991-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝素诱导血小板减少 | 临床3期 | 美国 | 2019-05-16 | |
| 肝素诱导血小板减少 | 临床3期 | 波斯尼亚和黑塞哥维那 | 2019-05-16 | |
| 肝素诱导血小板减少 | 临床3期 | 加拿大 | 2019-05-16 | |
| 肝素诱导血小板减少 | 临床3期 | 法国 | 2019-05-16 | |
| 肝素诱导血小板减少 | 临床3期 | 德国 | 2019-05-16 | |
| 肝素诱导血小板减少 | 临床3期 | 意大利 | 2019-05-16 | |
| 肝素诱导血小板减少 | 临床3期 | 波兰 | 2019-05-16 | |
| 肝素诱导血小板减少 | 临床3期 | 俄罗斯 | 2019-05-16 | |
| 肝素诱导血小板减少 | 临床3期 | 塞尔维亚 | 2019-05-16 | |
| 脑卒中 | 临床3期 | 美国 | 1995-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
GlobeNewswire 人工标引  | N/A | 233 | (adults patients) | 衊窪壓鬱製鹽壓鬱鬱觸(淵餘鏇觸獵鬱衊範衊構) = 壓選製鹹襯餘蓋觸簾膚 獵夢積簾蓋齋壓遞網築 (繭壓窪廠範鏇鹹醖齋範 ) 更多 | 积极 | 2024-08-29 | |
(pediatric patients) | 衊窪壓鬱製鹽壓鬱鬱觸(淵餘鏇觸獵鬱衊範衊構) = 網鬱蓋餘醖醖窪鹽積獵 獵夢積簾蓋齋壓遞網築 (繭壓窪廠範鏇鹹醖齋範 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用